Author(s) |
Duke, Carleigh
Parker, Suzanne L
Zam, Betty B
Chiong, Fabian
Sajiv, Cherian
Pawar, Basant
Ashok, Aadith
Cooper, Brynley
Tong, Steven Y C
Janson, Sonja
Wallis, Steven C
Roberts, Jason A
Tsai, Danny
|
Publication Date |
2024-11-04
|
Abstract |
To describe the population pharmacokinetics of cefazolin in infected hospitalized patients requiring intermittent haemodialysis (IHD).This prospective population pharmacokinetic study was conducted in IHD patients prescribed cefazolin 2 g three times weekly. Plasma samples were collected at prespecified timepoints and assayed for total and unbound concentrations using validated LC. Pharmacokinetic modelling and dosing simulations were performed using Pmetrics®. PTA in plasma suitable for MSSA (unbound trough concentrations of ≥2 mg/L for the final 24 h of a 72 h interval) were simulated for different dosing regimens. A PTA of ≥95% was deemed acceptable.A total of 260 cefazolin concentrations (130 total, 130 unbound) were collected from 16 patients (14 female) with a median age of 51 years. The median (IQR) pre-dialysis unbound cefazolin concentration for a 3 day dose interval trough was 17.7 (13.5-31.4) mg/L. The median (IQR) unbound fraction was 0.38 (0.32-0.46). The lowest pre-dialysis unbound concentration was 9.1 mg/L. A two-compartment model with a complex protein-binding component adequately described the data. The mean unbound cefazolin CL during IHD was 16.4 ± 4.26 L/h, compared with 0.40 ± 0.19 L/h when dialysis was off. Duration of time on haemodialysis (TOH) was the only covariate supported in the final model. The 2 g three-times-weekly regimen was associated with a PTA of 99.7% on dosing simulations to maintain unbound concentrations of ≥2 mg/L with TOH of 6 months. The 1 g three-times-weekly post-dialysis was associated with a PTA of 95.4%.A 2 g three-times-weekly post-dialysis cefazolin regimen is supported for MSSA infections.
|
Affiliation |
College of Medicine and Public Health, Flinders University, Corner Skinner and Simpson Streets, Darwin 0870, Northern Territory, Australia.
University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.
Pharmacy Department, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Department of Medicine, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Department of Nephrology, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Department of Medicine, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Pharmacy Department, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Department of Nephrology, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.
University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.
Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, QLD, Australia.
Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.
College of Medicine and Public Health, Flinders University, Corner Skinner and Simpson Streets, Darwin 0870, Northern Territory, Australia.
University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.
Pharmacy Department, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
|
Citation |
J Antimicrob Chemother . 2024 Nov 4;79(11):2980-2989. doi: 10.1093/jac/dkae318.
|
ISSN |
1460-2091
|
OrcId |
0009-0002-3093-7403
0000-0002-6124-7475
0000-0002-1368-8356
0000-0002-2392-9854
0000-0001-6218-435X
0000-0002-7059-8808
|
Pubmed ID |
https://pubmed.ncbi.nlm.nih.gov/39255245/?otool=iaurydwlib
|
Link | |
Subject | |
MESH subject |
Humans
Cefazolin
Middle Aged
Female
Male
Renal Dialysis
Anti-Bacterial Agents
Prospective Studies
Aged
Adult
Hospitalization
Bacterial Infections
Drug Administration Schedule
|
Title |
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
|
Type of document |
Journal Article
|
Entity Type |
Publication
|
Name | Size | format | Description | Link |
---|